Operator
Good afternoon, this is the Chorus Call conference operator. Welcome and thank you for joining the Stevanato Group half-year 2026 financial results conference call.
As a reminder, all participants are in listen-only mode and after the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing * and 0 on their telephone.
At this time, I would like to turn the conference over to Ms. Lisa Miles, Chief Communication and IR Officer.
Please go ahead, madam.
Lisa Miles
Good morning, and thank you for joining us. With me today is Franco Stevanato, Chairman and Chief Executive Officer, and Marco Dal Lago, Chief Financial Officer.
We have posted a presentation to accompany today's results on the Investor Relations page of our website, which can be located under the Financial Results tab. I want to remind everyone that some statements being made today are forward-looking and based on current expectations.
Actual results may differ materially due to risks outlined in item 3D, risk factors, of our most recent annual report on Form 20-F filed with the SEC. Please review the Safe Harbor statement included at the beginning of today's presentation and in our press release.
The company undertakes no obligation to revise or update these forward-looking statements except as required by law. Today's presentation may include non-GAAP financial information.
Management uses these measures internally to assess performance and believes they may be helpful for investors in evaluating the quality of our financial results, identifying trends in our performance, and providing meaningful period-to-period comparisons. For reconciliation of these non-GAAP measures, please refer to the company's most recent earnings press release.
With that, I'll hand the call over to Franco Stevanato.
Franco Stevanato
Thank you for joining us. Today, we review our second quarter performance, share an update on market trends in our two segments, including our investment projects, and discuss the current environment.
Our second quarter financial results were largely in line with our expectations, highlighted by solid revenue growth and a better mix of high-value solutions that drove expanded margins and adjusted EBITDA of 26%. Revenue grew 8% year-over-year, driven by a 9% revenue increase in the Biopharmaceutical and Diagnostic Solutions segment, which offset a slight decline in the Engineering segment.
Revenue from high-value solutions grew 16% and represented 45% of total company revenue in the second quarter of 2026, driven by a 30% increase in revenue from biologics, the fastest-growing end market. Revenue related to GLP-1s was approximately 22% to 23% of total company revenue.
As we disclosed this morning, we completed the divestiture of our California-based subsidiary, Balda-C. Brewer, which specializes in contract manufacturing services primarily for consumables and point-of-care diagnostic applications.
This initiative represents another step consistent with our long-term goal to continue optimizing our footprint and accelerating the transition towards more complex, differentiated, and integrated drug delivery systems. On behalf of management, I would like to thank the Balda team for their dedication and contribution to our group over the years.
Demand for injectable biologics remains strong, with more than 9,000 injectable assets in the global drug pipeline undergoing clinical evaluation or registration, and more than 60% of those are biologics. Our strategy is firmly anchored in the higher-value subsets of the market, and the business is positioned as a leader in biologic applications.
The rapid growth of biologics, GLP therapies, and increasing patient adoption of the self-administration of medicines is reshaping how pharmaceutical companies approach product development and commercialization. Drug delivery systems are playing an increasingly strategic role in the success of injectable therapies.
As a result, we see strong customer demand for integrated solutions that combine device innovation, manufacturing expertise, and supply chain reliability. We believe our broad portfolio of drug delivery platforms and our end-to-end capabilities position Stevanato Group well to support this evolution.
With this goal in mind, we are extremely happy that one of our pharmaceutical customers has received regulatory approval in several European countries for a liraglutide-based therapy that incorporates our proprietary Alina variable dose pen platform. The approval represents an important commercial milestone for our proprietary drug delivery systems and includes two Alina variants for both diabetes and weight management applications.
This important customer project also embeds our world-class cartridge technology into the Alina pen platform, harnessing the power of our integrated capabilities. Our proprietary devices are manufactured at our facility in Germany, which plays a pivotal role in serving our global pharma and biotech partners.
While Alina addresses the need for a variable dose pen platform, we also see a growing market opportunity for treatments that require strict patient adherence to dosing regimens. In response to customer feedback, we recently introduced D-Ora to meet this need.
D-Ora is a novel, multi-use, fixed-dose pen injector system compatible with pre-filled cartridges, delivering volume up to 3 ml. This new product will take time to get to commercial stage, but we see this as a promising future opportunity.
Our customer needs are clear, pointing to solutions that enhance patient usability and adherence, de-risk supply chain, provide a better answer to new drug product requirements of modern formulations, and lastly, increase the combination products' sustainability and cost efficiency profile. We believe we have the right set of expertise and competencies to support our customers with a broad and unique value proposition.
Let's turn our attention to the Engineering segment. We are pleased with the continued operational and financial progress in the business.
Our second quarter results demonstrate that the initiatives taken under the optimization plan are yielding positive results. Overall, the operations have stabilized, and we are continuing to execute our optimization plan.
As we mentioned last quarter, the teams are laser-focused on sales and marketing efforts to expand our opportunity set. We made good progress during the second quarter in winning new orders.
We are cautiously optimistic, but sales cycles are longer today than in previous years. Let's turn to an update on our growth projects in the US and Italy.
In the second quarter, we remained focused on scaling and executing our growth investments with a disciplined approach, strengthening our operational maturity while expanding capacity to meet customer demand. Starting from Fishers, we recently completed the initial performance qualification on the first EZ-fill vial line, and we expect to launch customer validation in the near term.
The build-out for our first device program remains on track, and we continue to expect commercial production to begin later this year. As these initiatives come together in Fishers, we are expanding our commercial capabilities and reinforcing our position for future growth.
Turning to Latina, the syringe ramp-up is ongoing as we continue to validate new customers. In addition, our next-generation RTU 400 cartridge line is expected to be completed and installed in the next couple of months, with commercial production expected in 2027.
In summary, our second quarter results were in line with our expectations, reflecting the continued strength of our strategy. We are positioning the business around the most attractive areas of the market, particularly biologics, GLP-1 therapies, and integrated drug delivery systems.
The divestiture of Balda-C. Brewer and our continued investment in platforms such as Alina and other premium products reinforces our focus on higher-value, differentiated solutions that address the evolving needs of our pharmaceutical customers.
At the same time, we're making progress in improving the Engineering segment and advancing our growth investments. I'll turn the call over to Marco for a review of our financial performance.
Marco Dal Lago
Thanks, Franco. Before I begin, I'd like to clarify that all comparisons refer to the second quarter of 2025 unless otherwise specified.
Let's start on page 10. In the second quarter of 2026, revenue grew 8% to $302 million both on a reported basis and at constant currency rates.
This was driven by a 9% growth in the BDS segment, which offset a 2% revenue decline in the Engineering segment. Revenue from high-value solutions increased 16% in the second quarter to $135.9 million and accounted for 45% of total revenue.
In the second quarter of 2026, gross profit margin increased 60 basis points to 28.7%. This was driven by the combined improvements in Latina and Fishers, which led to an increase in high-value solutions and improved marginality in the Engineering segment.
This was partially offset by the expected increase in depreciation, higher utility costs, and to a lesser extent, currency headwinds. In the second quarter of 2026, we completed the sale of our California-based subsidiary, Balda-C.
Brewer, which specialized in contract manufacturing services for consumables and point-of-care diagnostic applications. As a result, the company recorded one-time expenses of $12.2 million in connection with the sale and related transaction costs in the second quarter of 2026.
The subsidiary was expected to generate revenue of approximately $30 million in fiscal year 2026, and the transaction is expected to be accretive on the full-year margins. The sale of Balda-C.
Brewer and, to a lesser extent, higher startup expenses unfavorably impacted the group's operating profit margin in the second quarter. On an adjusted basis, operating profit margin increased 250 basis points to 18%.
As expected, the tax rate in the second quarter of 2026 was higher compared with the same period last year. As a reminder, the prior-year period benefited from a tax incentive which lowered the Italian statutory corporate income tax rate in fiscal year 2025, but the incentive was not available in 2026.
Additionally, there is no corresponding tax benefit on the sale of Balda-C. Brewer, which contributed to the increase in the effective tax rate in the quarter.
As a result of the one-time expenses related to the divestment and higher taxes, net profit totaled $23 million and diluted earning per share were 8 cents in the second quarter 2026. On an adjusted basis, net profit increased 20% to $37.6 million and adjusted diluted earning per share increased to 14 cents.
Adjusted EBITDA increased 21% to $78.7 million, and adjusted EBITDA margin increased 280 basis points to 26% in the second quarter of 2026. Moving to segment results on page 11.
In the second quarter of 2026, revenue from the BDS segment increased 9% to $266.2 million and grew 10% on a constant currency basis. Strong growth in premium Nexa syringes and, to a lesser extent, Alba syringes and EZ-fill vials led to a 16% increase in revenue from high-value solutions to $135.9 million, which represented approximately 51% of segment revenue.
Revenue from other containment and delivery solutions increased 3% to $130.3 million, mostly driven by growth in standard syringes and bulk cartridges, as well as variable compensation tied to a customer contract. Gross profit increased by $6.6 million in the second quarter of 2026, reflecting the combined improvements in the new plants as we continue to ramp up operations, which led to an increase in high-value solutions.
These positive trends were partially offset by the expected higher depreciation, an increase in utilities costs, and to a lesser extent, currency headwinds. As a result, gross profit margin decreased by 10 basis points to 31.1%.
The operating profit margin was impacted by the sale of Balda and declined 330 basis points to 15.8%. In the second quarter of 2026, revenue from the Engineering segment decreased 2% to $35.8 million due to lower sales in pharma visual inspection and glass converting, which offset growth in the assembling lines and after-sales activities.
In the second quarter of 2026, gross profit margin improved by 540 basis points to 12%, and operating profit margin increased 370 basis points to 2.9%. Ongoing efforts under our business optimization plan led to a strong margin expansion as the segment continues to make steady operational and financial progress.
Margins also benefited from improved operating results and a favorable mix in our Danish operations from newly secured projects in 2026, which is helping to refresh the project portfolio. While margins improved in the quarter and the team is making good progress in refreshing the backlog and the pipeline, we continue to remain somewhat cautious due to the elongated sales cycle and project phasing.
Please turn to the next slide for a review of our balance sheet and cash flow. We ended the quarter with cash and cash equivalents of $78.6 million and net debt of $360.3 million.
We believe we have adequate liquidity to fund our strategic priorities through a combination of cash on hand, available credit lines, cash generated from operations, and the ability to access additional financing. For the second quarter of 2026, capital expenditures totaled $52 million, mostly related to growth investment in the new plants and for our Alina device program in Germany and contract manufacturing activities.
In the second quarter of 2026, net cash flow from operating activities totaled $31.9 million. Cash used in property, plant, and equipment and intangible assets was $65.7 million.
Consequently, the company reported negative free cash flow of $32 million for the second quarter of 2026. Please turn to the next slide for an update of our full-year guidance.
The divestiture of our California-based subsidiary has been considered in our full-year guidance, with a reduction of revenue for fiscal 2026 of approximately $15 million. This revenue reduction is partially offset by better-than-anticipated currency translation and higher organic growth in our core business.
As a result, we now expect revenue in the range of $1,260 million to $1,280 million. The divestiture, while small, is expected to be accretive to margins at the central point of our guide, and we now expect adjusted EBITDA between $335 million to $345.2 million.
We are also narrowing the range for adjusted diluted EPS, which now expect to range between 60 cents to 62 cents for the fiscal year. Our full-year 2026 guidance assumes the following: the BDS segment is expected to grow on a reported basis high single digits; Engineering is expected to decline by mid-single digits to low double digits; high-value solutions are expected to range between 47% to 48% of total company revenue; free cash flow is expected to range from breakeven to positive $20 million.
We are updating the tax rate for 2026 and now expect a tax rate of approximately 28.2%, adjusted for the divestment. The higher tax rate is expected to be offset by lower-than-anticipated depreciation and amortization and financial expenses.
I will now hand the call back to Franco for closing remarks.
Franco Stevanato
Overall, we are pleased with our performance in the first half of fiscal 2026, which was in line with our expectations. It further highlights the continued strength of our core business and our ability to capitalize on the market opportunities in biologics, which remains the most attractive and fastest-growing end market.
This momentum reflects strong demand for premium containment and delivery solutions serving complex injectable therapies, including biosimilars, monoclonal antibodies, GLP-1 therapies, and other advanced treatments. With the rapid rise of patient adoption of drug delivery devices, pharmaceutical customers are increasingly seeking integrated partners that can combine device innovation, manufacturing expertise, and supply chain reliability.
Platforms such as Alina support this strategy by demonstrating Stevanato Group's ability to bring together drug containment and delivery device capabilities in a differentiated, commercially relevant solution. We believe we are uniquely positioned to respond to this market opportunity.
Overall, we are squarely focused on growing our premium high-value solutions in both drug containment and drug delivery systems to best position the company to capture the rising opportunities in injectable therapies, particularly biologics. Our goal is to move further up the value chain and deliver sustainable, profitable growth, expanded margins, and long-term shareholder value.
Operator
Thank you. This is the conference operator.
We will now begin the question and answer session. Anyone who wishes to ask a question may press * and 1 on their touchtone telephone.
To remove yourself from the question queue, please press * and 2. Please pick up the receiver when asking questions.
Anyone who has a question may press * and 1 at this time. We kindly ask you to limit to one question and one follow-up only, and join the queue again for any further questions.
We will pause for a moment as participants are joining the queue. First question is from Michael Ryskin, Bank of America.
Avantika Dhabaria
Hi, this is Avantika on for Mike. Thank you for taking our question.
You updated your BDS growth outlook from high single digits to low double digits to now high single digits. Can you walk us through what drove that change and whether it reflects only the divestiture or any other changes in the underlying business?
Thank you. Yes,
Marco Dal Lago
thanks for the question, Avantika. Marco is speaking.
The updated guidance on a reported basis, we updated to high single digit. Nevertheless, the organic growth is still double digit because we reduced by approximately $15 million related to the disinvestiture, and on the other side, we increased for approximately $8 million related to the lower currency headwind.
You probably remember at the beginning of the year, we started the year with estimation of $18 million of currency headwind on the top line, all related to BDS segment. After the first half of the year with approximately $9 million currency headwind, we can see now the year, the second part of the year, more more balanced.
We have a total currency headwind in the model of approximately $10 million. So, $8 million favorable in currency, $15 million headwind related to the divestment, and we increased couple of million our organic growth in our core business.
Avantika Dhabaria
Great. Thank you for that clarification.
Then, as your GLP-1 exposure continues to increase, are you seeing growth broaden across the non-GLP-1 biologics as well, or is still GLP-1 the primary growth driver for HVS?
Franco Stevanato
Yes, thank you for the question. We all know that the GLP-1s are a phenomenal drug class that we'll expect to continue and to represent a strong, long-term durable tailwinds in the next year.
Where Stevanato Group is laser focus in this moment and the next year to come is on biologic. Biologic is a phenomenal opportunity for Stevanato, just to give you some number.
In the industry, there are more than 9,000 injectable assets in the global drug pipeline, and more than 60% are going to be with biologic to injection, self-administration. The reason why we are heavily investing through our plants in Europe, in United States, and we are heavily invested in order to expand our proprietary devices in term of drug delivery system, EZ-fill platform, in order to try to maximize our leadership position in the next year to come in biologic.
In 2026, we have delivered 6% of growth in biologic. Most of the reason is because we are at the early stage.
Are more revenue that we are generating from client that are in Phase 2 and Phase 3. We have started the big strategic goal is to be big, five with in this molecule that will represent tailwinds in the next year to come.
Avantika Dhabaria
Great. Thank you so much.
Operator
Next question is from David Windley, Jefferies.
David Windley
Hi, good morning, good afternoon. Thanks for taking my question.
Wanted to follow up on that and your comments I think in your prepared remarks about a move toward premium high-value solutions. Franco, I was hoping, one, you could talk about which products in your portfolio you consider to be the premium products within high-value solutions, and then, presuming Alina is one of those, how many countries and kind of what is the size of the opportunity with this recent approval of Alina for liraglutide?
Thanks.
Franco Stevanato
Thank you, David. Let me share that we are so excited and proud because it took in Stevanato 8 years to develop and to launch on the market this Alina product.
We start with our R&D department in 2008 years ago, even more. This is the reason why in 2016 we acquired the what's so-called Balda Germany, and today is going to become a sort of as hub in order to produce this IP product for Stevanato.
The fact that now we were validated in Europe in a said many country for this Alina product both for diabetes and for weight loss management treatment is going to recognize that Stevanato today is play in what we so-called Champions League, because we are not serving anymore the product through the CMO business model, but we are serving our IP product and the differ that have Stevanato that we don't sell only the drug delivery system, we are selling what we so-called integrated system approach where there are always our glass cartridge inside. Today, we are delivery our Alina pen and our cartridge to what so-called a system integrator, are a specialized partner that are going to take care what is related to the devices, the cartridges, and the filling and the regulatory support in order to help many big international biosimilar clients, both in Europe and United States, to launch on the market this biosimilar.
Today, Alina is having very strong traction for what is related to liraglutide, what is the treatment of the weight losses. What I would like to underline, we are at a very early stage, because before this validation, there were a lot of prudent approach for many clients about the functionality of this device.
Today, this official registration is opening and boosting the traction of other validation worldwide, and where all this production, we are going to produce through our plant in Germany. Like I already mentioned last year, we already started last year to renovate and upgrade one big area of production in order to start in heavily industrial production for Alina in the next years.
In parallel, also, we start to develop and launch our D-Ora, that is an evolution of our Alina product that is first perfectly fitting for certain treatment where patient they need a strong accuracy of the doses. The fact that we are already registered on Alina is further helping to boost, even in the term, the adoption.
I want to say, sorry to use my Latin approach, that this is going to be maybe one of our most big milestone in 2027 2026.
David Windley
To follow up, I presume your enthusiasm suggests to me that Alina and I'll get the name wrong, Aora, are premium products. I'd love to hear what are the other ones that you consider premium within high value, and if you would, of the 47% to 48% of revenue that is high value, what percent of that is currently premium high value?
Thank you.
Franco Stevanato
Alina is in a range of premium product. The revenue around Alina are already captured in our guidance 2026, and most probably in the next year to come, Alina will generate a double-digit revenue growth in the Alina product.
Where we are also facing a strong attraction, strong success on the market is what we call our Alba syringes, because we launched these syringes many years ago for certain ophthalmic application. Today, we see more and more strong traction in customer that are going to adopt the monoclonal antibody.
Also here, we are heavily investing in capacity, David, here the plants in Piombino Dese, and the next phase, we're going also to move industrial capacity into the plants in Fishers in order really to serve the biologic market directly from Fishers.
David Windley
Thank you.
Franco Stevanato
You're welcome.
Operator
Next question is from Paul Knight, KeyBanc Capital Markets.
Paul Knight
Congratulations, Franco. The long-term potential, I think, is obvious with Latina and Fishers.
What capacity utilization will Fishers and Latina operate this year?
Franco Stevanato
Today, the demand that we have in Fishers and Latina is quite in all in 2026 for in particular for syringes, Nexa, Alba, and cartridges bulk, and cartridges ready to fill is quite strong, robust, Paul, for both plants. The way that we plan our investment are dedicated with capacity at program that we have with customer.
All the number of line that we have installed and validated in Latina, we continue to install and do the validation throughout 2026 in Fishers are with the direct program where the client is do the audit, do the validation, and then we have dedicated line. Our approach is always to maintain certain free capacity in order to enhance our plants, to have the flexibility also to do the sampling and the validation for the future program that we're going to start to host the next year to come.
Overall, the message is demand is robust is strong, but also is important to keep some space in order to perform the validation.
Marco Dal Lago
As a reminder, Paul, Marco is speaking, we plan to fully ramp up Fishers by the end of 2028. We still have way to go there and improving our production and financial performance throughout our next quarters.
Then,
Paul Knight
could you, Franco, give us an update on your creating Centers of Excellence within Engineering? Where are you in that program?
Franco Stevanato
Sure. Today, regarding the Engineering, we have two center: one is in Italy specialized in vision inspection machine and for customized line and for certain assembly technology, and Denmark is going to be specialized in particular for the sophisticated high-speed line for assembly.
The optimization plan initiative that we started more than one years ago, they are delivering positive results. In fact, you see, Paul, are translated also in our revenue, in our marginality, that are much better in this quarter.
This is starting to be a signal of trend for the future quarter. From Engineering point of view, the organization and the team are really moving in the right direction, also what we're starting to see positive signal because we are more and more having a good progress in winning new orders both with our historical clients, but also we're starting to build a rich pipeline for new clients, in particular for vision inspection.
Our goal is really to have a quarter-by-quarter an improvement in term of revenue and marginality in order to be back to original number in more and more in 2027. Also here, the division has started really to deliver good signal of in term of revenue and marginality.
Paul Knight
Thank you.
Franco Stevanato
Welcome.
Operator
Next question is from Larry Solow, CJS Securities.
Larry Solow
Great. Good afternoon, everybody.
Just a couple of questions. Can you give us just a little flavor maybe just on you mentioned GLPs 22%, 23% of revenue.
Can you just speak GLPs versus non-GLPs in the high-value products or biologics growth, give us an idea what that was. Sounds like GLPs grew faster than overall growth.
Can you give us any idea of that?
Franco Stevanato
Sure. Today, Franco speaking, the revenue on inside of the BDS segment around biologic represent approximately 42%.
We move where in 2022 we were approximately a little bit less than 20 20%, today move on more than 42%. In this moment, GLP-1 are representing a very visible revenue contribution inside of biologic because it's already commercial.
We are serving two big originator, and we are actively moving in order to maximize our validation through all the biosimilar, both through our syringes Nexa, cartridges ready to fill, and also we have many program around our drug delivery system. Is also true that we are so engaged with several hundred of clients, both big organization to small startup, in order to really try to maximize our penetration in all the biologic space.
Today, in the biologic space, we have delivered plus 6%, like was mentioning before, but because most of this program are at the early stage, they're not represented a big big revenue generation. If I can give you a sort of projection, GLP-1 is a well-established opportunistic tailwinds that will continue to grow in the next years, and biologic, it will be much more spread through many clients and many therapeutic area.
Then if you go to combine all this opportunity, is going to be much bigger in the next year to come compared to GLP-1.
Larry Solow
Great. Then a follow-up just on the Alina, if I could just a clarification.
It sounds like this approval culminates several years of work and this validation, feels like you're not building in a lot of revenue specifically to this approval this year, but this validation opens the door for several other approvals, and I imagine this is multi-year stuff, you must have other customers in the queue. Is that fair to say?
Franco Stevanato
Absolutely. We are in term of investment, in term of revenue, revenue around Alina are already captured in 2026 in our guidance.
What we can tell to you that we are heavily investing with the industrial commercial capacity in our plants in Germany the next 12, 24, 36 months in order really to be able to serve this growing demand. Like I mentioned to you before, we counted that Alina, it will help to generate double-digit revenue around Alina product in the next year to come, focalize in what we call our premium high-value solution product.
Today, we have done the first registration with a certain number of clients, first in Europe. In the second part of the year, we will receive additional validation in North America.
What is more important, the fact that now we have this registration on the market is helping to boost and push other traction from other clients, in particular in biosimilar space for what is related to the weight loss management treatment. This is the real strategic.
Our industry usually is a little bit prudent and conservative. Since there is no a real product on the market, some clients they are waiting.
Now that this is proven is opening a big, big opportunity the next year around our IP product.
Larry Solow
Got it. Great.
Appreciate that. Thank you.
Welcome.
Operator
Next question is from Brandon Deegan, Citi.
Lisa Miles
Brandon?
Brandon Deegan
Can you hear me?
Lisa Miles
Oh, yes. Thank you.
Excellent, Brandon. Yes, we can.
Brandon Deegan
Sorry about that. Don't know what happened there.
I was wondering if we could start off by unpacking the Engineering performance in 2Q. It saw a nice rebound off pain in 1Q and kind of towards the lower range of the commentary provided on the 1Q call.
I was wondering if you could unpack that a little bit, but then also kind of go into how kind of customer decision timelines have evolved throughout the quarter, and what kind of the backlog looks like as we head into the second half of the year.
Franco Stevanato
I have understood a question, sorry because there was a lot of noise in the microphone. You ask how is the situation with the backlog compared to the first part of the year to the second part of the year?
Brandon Deegan
Just if you can unpack the Engineering performance in 2Q.
Franco Stevanato
See, today, we have a healthy pipeline that is going to be step-by-step translate in orders. If you combine from the beginning of the year to the second part of the year, we are starting really to more and more move this pipeline into order.
In fact, we have a very strong progress in winning new orders, in particular for what is related to visual inspection machine, in particular in Europe, in Asia, and as technology for assembly for drug delivery system in Europe, in United States. We see quarter after quarter a progression in order to enlarge the confirmed orders compared to what was the order intake.
The trend is starting to become better and better quarter after quarters.
Brandon Deegan
Got it. Thank you.
Then I wonder if we could touch on the gross and operating margin assumptions for the full year. I believe though given the divestiture, I was wondering if you could just touch on those.
I believe the last guide had around 0 to 30 bps for gross margin and around 50 for operating. How does that change with the divestiture?
Thank you again, and congrats on the quarter.
Marco Dal Lago
Yes, thanks for the question. About our guidance, I'm staying at the center point of our guidance.
Our plan is to expand reported gross profit by 50 basis points approximately. If we exclude the one-timer event in second quarter, our plan is to increase our adjusted operating profit of 110 basis points compared with last year.
As mentioned in our press release, adjusted EBITDA margin, the center point of the guidance is expected to be at 26.8%, expanding 170 basis points compared with last year. This is driven by slightly improved margin in our BDS segment, improved gross profit margin in our Engineering segment, and disciplining cost management in SG&A and R&D expenses.
Brandon Deegan
Great. Thank you.
Operator
Next question is from Matt Larew, Stephens Inc. ):
Mac Etoch
Hey, good morning, and thank you for taking my questions. Maybe just to follow up on the previous answer, I think you touched on it a little bit, but the variable compensation that you highlighted within the presentation deck, how much was that, and how much of a benefit was that to 2Q margins?
Marco Dal Lago
Thanks for the question. Marco is speaking.
The variable compensation is tied to one specific contract we have with a long-lasting customer. It provides a fair compensation for a reduction in volumes compared with the committed volumes from the customer.
As a reminder, under the contract terms and condition, we have protection in place for changes in forecast. Variable consideration compensated us for the cost we had in the quarter in the first half of the year in term of capacity reservation, workers, labor, depreciation, and so on and so forth, plus a fair compensation of the missing margin.
):
Mac Etoch
Thanks for that, Marco. Maybe just to bear down a little bit more on that, is it possible to quantify how much of a benefit it was to the quarter?
Marco Dal Lago
No, it's not impacting in significant way the quarter. It's a fair compensation of the missing margin and the cost we had.
):
Mac Etoch
Got it. I appreciate that.
Thank you.
Operator
Next question is from Callum Timms, Morgan Stanley.
Jason Lai
Hi, this is Jason on for Callum. Thank you for taking our questions.
Maybe just a question on the Balda-C. Brewer divestiture.
Could you just walk us through the strategic rationale for divesting the business and the business profile? What was the growth profile of that business, and what was the HVS, non-HVS mix for that business?
Appreciate the comments that the spin-off was margin accretive, but was wondering if you could quantify that margin uplift. Thank you.
Franco Stevanato
Thank you. When in 2016 we decided to enter in the device space, we acted for two decisions: first to acquire Balda, where the big target was the industrial hub in Germany.
When we acquired this company, we discovered there was also a smaller operation in California in south of Los Angeles, we call Balda-C. Brewer, specialized more in contract manufacturing of standard consumable product.
When we are starting to develop our R&D center in Milano, more and more our attention and focus was to move the standard diagnostic in order to better serve molecular diagnostic. Now the real goal is really to build a value proposition for our biologic client in injection in order to deliver not only the glass, EZ-fill, but also together with the drug delivery system.
Now we are in 2026, where most of our investment are in order really to build capacity for drug delivery system. This plant that is not anymore strategic for Stevanato because it don't have any particular strategy to serve this biologic market, we have decided to pass to this program of divestiture in order really to remove some industrial setup not strategic for our biologic clients.
About the model, we had previously in our model approximately $30 million revenue for the year and slightly positive EBITDA. That's why we are, let's say, our margin is more accretive with the disinvestor.
This initiative really represents another step in order really to move the value chain and the product portfolio of Stevanato, our industrial setup, more versus some accretive high-value solution product in order to better serve biologic market. This is one another step like what we have already done last year, we started to slow down a little bit our attention in Europe for the standard ampoules.
Jason Lai
Great. No, thank you for the color.
I guess maybe just a question on generic GLP-1s. We've seen patents for semaglutide expire in 2026 in Canada, India, Brazil, and some early generic GLP launches.
I'm wondering will generic GLP-1s largely use high-value solutions as the current branded GLP-1 drugs, and could you just talk about the opportunity from the generics?
Franco Stevanato
Today, we serve by the GLP-1 market to our originator, to our biosimilar, we serve the syringes Nexa, we serve the cartridges in bulk, but mostly cartridges ready to fill, and also we are starting to maximize with all the biosimilar that are entered in the market. Today, we see that all the biosimilar, they are practically using the same type of administration, then injection.
Stevanato is acting to serve to this biosimilar that are still at the early phases through syringes Nexa, cartridges ready to fill, but even more, we are starting really to deliver what we call the fully integrated system, where we're going to add also our proprietary device like Alina. This is valid for practically all the region, like I was mentioning you before.
We're starting to serve some European market, now the next phase it to be North America, Latin America exactly for this type of configuration, where there will be or either our syringes or there would be our cartridges plus the Alina product.
Jason Lai
Great. Appreciate the color.
Thank you.
Operator
Next question is from Chad Wiatrowski, TD Cowen.
Chad Wiatrowski
Hey, everyone. Beyond the Balda divestment, are there other segments or SKUs that you view as non-core and could potentially be under strategic review currently?
Franco Stevanato
At the moment, we don't have relevant initiative under the radar. It's also true that if you look from the day of the IPO to today, we invested more than $1.3 billion mostly around high-value product.
It's also true that if you look the strategy of our organization, starting from sales, R&D, product management, and operation, and supply chain, the goal is to build a leadership position in biologic. Indirectly, there are step-by-step a little bit less attention in what we call non-high-value product or certain bulk activity, make an example, ampoules that we serve from Europe, from Brazil, some other standard plastic component for diagnostic, where step-by-step we would like really to reconvert and to use this space in order to better serve our EZ-fill platform, our drug delivery solution.
For sure, this is something that we do step-by-step gradually because we want really to evolve our value proposition in the next one, two, three, four years. Today, no other relevant initiative.
Chad Wiatrowski
Got it. That's helpful.
Then, yeah, it was encouraging to see the Alina approvals. Is there an incentive for pharma customers to order from providers who offer both the glass combined with the proprietary device?
Are these approvals symbolic of maybe a broader shift over time where companies who offer more integrated solutions are positioned stronger in a market that's historically been pretty fragmented? Thanks for the questions.
Franco Stevanato
Today, all over, there is a trend of the pharma industry to outsource as much as they can the supply chain. They can use specialized CMO, they can use company like Stevanato that we sell the integrated offering.
Today there is more and more a visible trend where pharma customer, they try to outsource a big portion of supply chain. The advantage of this system integrator provider, they're very proactive that they don't perform only the filling, they are helping this international biosimilar company really to take all the type of activity in order really to collect the devices, the cartridges, to the filling, regulatory support, in order to enhance this biosimilar to focalize in the go-to-market.
More and more, we see this trend in the industry today. Stevanato proactively what we do, we use our tech center, we use our specialized hub in Italy, in United States in order to try to capture as much as we can big pieces of this supply chain and increase our value proposition.
Operator
Next question is from Curtis Moiles, BNP Paribas.
Curtis Moiles
Hey, thank you for taking my questions. First, just on GLP-1s, obviously, that stepped up again as a percentage of revenue compared to 1Q 2026.
Maybe you can talk about how you're seeing that progress through the year, and whether your sort of mid-teens growth guidance remains intact there?
Marco Dal Lago
Starting from the guidance, we can see a double-digit growth compared to last year, still a significant growth. About the overall market situation, I would hand over to Franco to add more.
Franco Stevanato
Correct. Today, in the industry, what we see that GLP-1 is you really we are really what we call at the beginning of this journey, because we are if you look all the potential opportunity that we have to our originator clients and even more with the biosimilar that are very active in any region of the world, I think that we are at the really at the tip of the iceberg.
Today, there are less than 10% of patient penetration in a total potential addressable patient, that is 1.5 billion. We expect that this will continue to represent a strong, long-term durable tailwinds for all the industry, including Stevanato.
The strategy of Stevanato is really to maximize our penetration through the originator, like we have done in the past with with insulin, and in parallel, try to maximize our presence, our validation in all the biosimilar, not only through our EZ-fill platform, but also with our drug delivery system, because I think the next 5 to 10 years, there'll be a lot of opportunity to stay in double digit only through GLP-1 in the next years. What is important again to underline for the second time, that the GLP-1, we want to have a very strong, opportunistic approach, but is limited to one therapeutic class.
The real goal of Stevanato and the reason why we are done the IPO in 2021 in order to finance and build this huge hub in United States and increasing capacity in Europe is because all the biologic market is growing, spread to several tens of hundred of clients and several therapeutic area, is where we want really to play a visible role with all our integrated value proposition, starting from EZ-fill product, syringes, cartridges, and vial, and move up the value chain to our drug delivery system, and to certain clients through our tech center, we're starting to perform also fill and finish for non-human use. This is where we really want to focalize SG the next 5 to 8 years.
Curtis Moiles
Thank you. Then moving to the BDS gross margin, I'm just wondering is this sort of 2Q level a good jumping-off point for the remainder of the year?
Should we see it ramp a little bit from here or could it maybe come off a bit?
Marco Dal Lago
Yes, we expect for BDS to match or overtake the gross profit margin we had in 2025. We're expecting Q3 and Q4 further margin expansion in our BDS segment, driven by the growth in Fishers and Latina, and driven by the fact that we expect a stronger second half of the year, a better leverage on our fixed expenses, again, mainly driven by Fishers and Latina.
Curtis Moiles
Got it. Thank you.
Operator
Next question is from Matt Larew, William Blair.
Matt Larew
Hi, good morning, and thanks for taking my question. Obviously, a lot's been covered.
Just one for me. I know you had a press release a few days ago on the Alina approvals.
You've mentioned it a couple times today. I know that these were already approved, I'm curious if these are new or different configurations and thus perhaps a new share opportunities for Stevanato.
Again, you've covered it a little bit, but just what these approvals mean for you in terms of long-term aspirations in the device space? Thanks.
Franco Stevanato
Practically, Matt, with this approval in Europe, and there will be additional approval in the second part of the year in United States, we have a big number of clients, we are going to start to deliver our Alina pen for this liraglutide product together with our cartridges. Translated in number, we are starting to generate revenue with selling Alina in 2026, but even more, there will be a progression because this client are launching the product on the market.
The configuration will be Alina product in the different format and with our cartridges.
Matt Larew
Thank you.
Franco Stevanato
You're welcome.
Operator
Ms. Miles, gentlemen, there are no more questions registered at this time.
Lisa Miles
Thank you very much to everyone for joining us for Stevanato Group's second quarter 2026 earnings call. We look forward to speaking with you in the future, and enjoy the rest of your summer.
Operator
Ladies and gentlemen, thank you for joining. The conference is now over.
You may disconnect your telephones.
Already premium?